Regulatory Compliance and FDA Status Monitoring

The contract requires ongoing monitoring and documentation to ensure The Shield™ retains its FDA approval for use in colorectal cancer screening throughout the term, including any option years. This involves maintaining regulatory compliance with federal standards, tracking regulatory updates, and providing timely submissions or supporting materials as needed to sustain authorization for the device in clinical use. The work is tied directly to the continued validity of the product’s clearance under FDA regulations for a critical public health application. The contract is structured as a subcontract under the Department of Health and Human Services, specifically managed by the Phoenix Area Indian Health Service, with performance designated to take place in Elko, Nevada, 89801. It falls under NAICS code 541611, indicating it relates to administrative management and general management consulting services, likely reflecting the advisory and compliance-focused nature of the tasks. The solicitation was posted on April 23, 2026, with responses due by May 10, 2026, signaling a rapid procurement timeline for specialized regulatory expertise. There is no set-aside designation specified, and the contract remains focused on sustaining regulatory status rather than product development or commercialization.